Oslo, Norway, 30 November 2021

Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on
CD37-targeted therapies for haematological cancers and immune diseases, will
today host an R&D day starting at 14:00 CET/ 13:00 GMT/ 08:00 ET.?The meeting
will be held via a live webcast.

Presentations will be delivered by Dr Leo I. Gordon, MD, FACP, a global key
opinion leader in haematology and members of Nordic Nanovector's executive team.

Erik Skullerud, Nordic Nanovector's CEO, commented: "We are pleased to share our
vision and strategy for creating value from Betalutin® - a potential 'pipeline
in a product' for treating different types of non-Hodgkin's lymphoma (NHL) - as
well as through the development of exciting opportunities that leverage the
company's deep expertise and experience in CD37 biology. CD37 is a well
-established and validated therapeutic target for a range of haematological
cancers and immune diseases. Nordic Nanovector has a fantastic opportunity to
build a leadership position around this target and already has several early
-stage assets that could form the foundation for future growth."

The webcast can be accessed from?www.nordicnanovector.com in the section:
Investors & Media and a recording will also be available on this page after the
event. The full programme for the event and presentation slides are available
today from 07:00 CET at www.nordicnanovector.com  in the section: Investors &
Media/Reports and Presentations/R&D Day 2021.

More detail on what will be presented is as follows:

Mr Skullerud, CEO will outline the strategic vision for Nordic Nanovector beyond
the pivotal Phase 2b PARADIGME trial for Betalutin®, including its development
in other NHL indications where Betalutin®'s unique profile could address unmet
patient needs. Mr Skullerud will also introduce the emerging CD37-targeting
opportunities within the company's portfolio.

Dr Leo I. Gordon, MD, FACP - Abby and John Friend Professor of Cancer
Research?at the Northwestern University Feinberg School of Medicine, whose
research focus is to improve the outcome of patients with lymphoma - will
discuss the remaining unmet medical needs in relapsed follicular lymphoma (FL),
particularly in elderly and frail populations. He will also provide an update on
the evolution of the treatment algorithm given the recent introduction of
several novel therapies. He will look at the potential role of next generation
radioimmunotherapies in addressing these challenges.

Pierre Dodion, MD, incoming Nordic Nanovector CMO, will discuss the planned
expansion of the Betalutin® clinical programme for earlier line treatment of FL
and expansion to other NHL subtypes such as diffuse large B-cell lymphoma
(DLBCL). He will also discuss how insights from earlier clinical studies are
expected to inform development of Betalutin® in these indications.

Marco Renoldi, MD, COO, will discuss how targeted radioimmunotherapy can be
integrated into NHL care pathways, focusing on an independent government affairs
project - the Radioligand Therapy Readiness Assessment Framework - funded in
part by Nordic Nanovector and led by The Health Policy Partnership (HPP) to
realise the potential of radioligand therapy (radioimmunotherapy).

Lars Nieba, PhD, CTO, will discuss progress being made in preparing the CMC
(Chemistry, Manufacturing and Controls) component essential for the BLA
(Biologics License Application) of Betalutin®. He will also cover other key
steps the company is undertaking to become launch ready, pending a successful
clinical trial and regulatory process.

Maureen Deehan, PhD, Head of Corporate Development and Strategy, and Jostein
Dahle, PhD, CSO, will discuss the rationale behind the company's focus on CD37
as a target, and the emerging opportunities for product development and value
creation within its pipeline. These opportunities include:

  · Humalutin®, a radioimmunotherapy candidate based on a chimeric anti-CD37
antibody conjugated to lutetium-177 for NHL,
  · Alpha37, an alpha-emitting radioimmunotherapy candidate based on a chimeric
anti-CD37 antibody conjugated to lead-212, currently being explored with partner
Oranomed for relapsed refractory chronic lymphocytic leukaemia,
  · A fully humanized anti-CD37 antibody with potential in haematological
cancers and autoimmune diseases, and
  · A CD37 DOTA CAR-T cell opportunity in haematological cancers, which was
recently the subject of a research collaboration with the University of
Pennsylvania

A Q&A session will follow the presentations.

For further information, please contact:

IR enquiries

Malene Brondberg, CFO

Cell: +44 7561 431 762

Email:?ir@nordicnanovector.com

Media enquiries

Mark Swallow/Frazer Hall/David Dible (MEDiSTRAVA Consulting)

Tel: +44 207 638 9571

Email:?nordicnanovector@medistrava.com

About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs. The Company aspires to become a
leader in the development of CD37-targeted therapies for haematological cancers
and immune diseases. Nordic Nanovector's lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to
advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with
substantial unmet medical need, representing a growing market forecast to be
worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing
rights to Betalutin® and intends to actively participate in the
commercialisation of Betalutin® in the US and other major markets.

Further information can be found
at?www.nordicnanovector.com (https://nam10.safelinks.protection.outlook.com/?url
=
http%3A%2F%2Fwww.nordicnanovector.com%2F&data=04%7C01%7CMark.Swallow%40medistrav
a
.com%7Cb7a23ba8eace4c1e863308d97799ed1f%7C5c24475f929349d0b4e1ba6d190e92f9%7C0%7
C
0%7C637672326009184815%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luM
z
IiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000&sdata=NOyVW%2B%2F3LdP8et7SyKO6Bze%2FFG2Z
%
2F4IBg8BfYb%2B87dU%3D&reserved=0).

Forward-looking statements

This press release contains certain forward-looking statements. These statements
are based on management's current expectations and are subject to uncertainty
and changes in circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their nature, will
have an impact on Nordic Nanovector's business, financial condition and results
of operations. The terms "anticipates", "assumes", "believes", "can", "could",
"estimates", "expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case, their
negative, or other variations or comparable terminology are used to identify
forward-looking statements. These forward-looking statements are not historic
facts. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in the forward
-looking statements. Factors that could cause these differences include, but are
not limited to, risks associated with implementation of Nordic Nanovector's
strategy, risks and uncertainties associated with the development and/or
approval of Nordic Nanovector's product candidates, ongoing and future clinical
trials and expected trial results, the ability to commercialise Betalutin®,
technology changes and new products in Nordic Nanovector's potential market and
industry, Nordic Nanovector's freedom to operate (competitors patents) in
respect of the products it develops, the ability to develop new products and
enhance existing products, the impact of competition, changes in general economy
and industry conditions, and legislative, regulatory and political factors. No
assurance can be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any forward
-looking statements, whether as a result of new information, future events or
otherwise.

This information is subject to a duty of disclosure pursuant to Sections 4-2 and
5-12 of the Securities Trading Act.